THE EFFECT OF SGLT2 INHIBITORS ON VOLUME-RELATED LABORATORY AND METABOLIC PARAMETERS IN OLDER ADULTS: A 6-MONTH RETROSPECTIVE STUDY

Aykut HACIÖMEROĞLU, Aydın ÇİFCİ, Zekiye Nur ÖZTÜRK, Artuner VARLIBAŞ, Şule ÇIRAKOĞLU

Intercontinental Journal of Internal Medicine - 2026;4(4):76-83

Department of Medical Oncology, Sakarya Training and Research Hospital, Sakarya, Turkiye

 

Aims: This study evaluated the effects of sodium-glucose cotransporter-2 (SGLT2) inhibitor therapy on volume-related laboratory parameters, blood pressure, and pulse rate in geriatric patients with type 2 diabetes (T2D) mellitus without major comorbidities. Methods: This retrospective study included patients aged >=65 years with isolated T2D who initiated SGLT2 inhibitor therapy for the first time. Patients with hypertension, cardiovascular disease, chronic kidney disease, or diuretic use were excluded. Hematological, renal, biochemical, and electrolyte parameters, together with systolic (SBP) and diastolic blood pressure (DBP) and pulse rate, were assessed before treatment and after 3 and 6 months. Repeated-measures parametric or non-parametric tests were used as appropriate. Results: Among 206 patients, 190 received dapagliflozin and 16 empagliflozin. Body weight, body-mass index (BMI), waist circumference, and blood pressure decreased significantly (p<0.001). Renal function markers (urea, creatinine, and blood urea nitrogen [BUN]/creatinine ratio) increased, whereas estimated glomerular filtration rate (eGFR) decreased. Sodium and albumin levels increased, while uric acid levels decreased (all p<0.001). Significant reductions were observed in glucose and HbA1c levels. Triglycerides (TG) decreased, whereas total cholesterol, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol increased. Hemoglobin, hematocrit, red blood cell (RBC), and platelet counts increased significantly (p<0.001). Most changes were more pronounced during the first 3 months and then approached a plateau. Conclusion: SGLT2 inhibitors improved anthropometric measures, blood pressure, hematological indices, and glycemic control in geriatric patients without comorbidities. Early changes in volume-related parameters highlight the importance of close monitoring during treatment initiation while supporting the safe and effective use of SGLT2 inhibitors in this population.